ArticleJournal of hepatocellular carcinoma2025
Functional Liver Imaging Score to Predict Clinically Significant PHLF for Hepatocellular Carcinoma After Resection.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop a model based on Functional Liver Imaging Score (FLIS) to estimate the risk of clinically significant post-hepatectomy liver failure (PHLF) for hepatocellular carcinoma (HCC) after resection. Patients and Methods: This retrospective study analyzed 885 patients with HCC who undergoing liver resection at our medical center between January 2017 and December 2021. Patients were randomly (7:3) assigned to development (n=620) or internal validation (n=265) cohorts. Univariable and multivariable logistic regression analyses were performed to identify independent risk factors for clinically significant PHLF, defined as grade B or C PHLF by the International Study Group of Liver Surgery. Predictive performance was assessed by the area under receiver operator characteristic curves (AUC). Results: Clinically significant PHLF occurred in 7.7% of the development cohort and 7.2% of the internal validation cohort. Multivariate analysis identified FLIS, major resection and ALBI score as independent predictors of clinically significant PHLF, and a model combining these three variables predicted failure in the development cohort (AUC 0.746, 95% CI 0.673-0.820) and internal validation cohort (AUC 0.717, 95% CI 0.595-0.838). The same model also predicted mortality within 90 days after surgery in the development cohort (AUC 0.704, 95% CI 0.575-0.832) and internal validation cohort (AUC 0.717, 95% CI 0.586-0.848). In both cohorts, overall survival rate was significantly lower among patients whom the model placed at high risk of clinically significant PHLF than among those at low risk. Conclusion: The combination of FLIS and other easily acquired clinical data may reliably predict clinically significant PHLF and mortality in hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.